|
KMID : 1009020230210030594
|
|
Clinical Psychopharmacology and Neuroscience
2023 Volume.21 No. 3 p.594 ~ p.598
|
|
|
Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting
|
|
Lee Kyung-Ho
Han Tae-Sun
Han Chang-Su
Bahk Won-Myong
Lee Soo-Jung
Ashwin A. Patkar
Prakash S. Masand
Pae Chi-Un
|
|
|
Abstract
|
|
|
Objective: This study tried to observe additional benefit of agomelatine (AGO) treatment for major depressive disorder (MDD) in routine practice.
Methods: Retrospective chart review (n = 63) was conducted for additional benefit of combination with or switching to AGO in MDD patients without full remission. The primary endpoint was the mean change of Clinical Global Impression-Clinical Benefit (CGI-CB) total scores from baseline to the endpoint. Additional secondary endpoints were also collected.
Results: The changes of CGI-CB (Z = ?3.073, p = 0.002) and Montgomery-Asberg Depression Rating Scale (Z = ?3.483, p < 0.001) total scores were significantly decreased from baseline to the endpoint, respectively. At the endpoint, the remission rate was 22.6% (n = 18) and 28.6% of patient had improvement in CGI-CB total scores at the endpoint. No significant adverse events were observed.
Conclusion: This study has shown additional benefit of AGO treatment as combination or switching agent for MDD patients without full remission in routine practice. However, adequately-powered and well-controlled studies are necessary for generalization of the present findings.
|
|
|
KEYWORD
|
|
|
Agomelatine, Depression, Pharmacotherapy, Clinical benefit
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|